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1. Introduction 
The formation and metabolism of bile acids involve 
a number of hydroxylations. Generally, the hydroxy- 
lations of the steroid nucleus are catalyzed by the 
microsomal fraction of liver homogenate with the 
addition of NADPH and with the participation of 
molecular oxygen [I] . The same subcellular fraction 
catalyzes the hydroxylation of various drugs, aliphatic 
hydrocarbons, fatty acids and steroid hormones [2]. 
Many of these reactions have been shown to involve 
the participation of a flavoprotein, NADPH-cyto- 
chrome c reductase, and a carbon-monoxide binding 
pigment, cytochrome P450, as electron carriers be- 
tween NADPH and oxygen [2]. It has also been shown 
that administration of drugs, e.g. phenobarbital, in- 
duces increased activity of liver microsomes to hydra 
xylate drugs as well as heptane, laurate and several 
steroid hormones [2] . These findings have led to the 
suggestion that a single enzyme system might catalyze 
the different hydroxylations [3,4]. To examine this 
possibility and to obtain further information concern- 
ing the properties of the hydroxylases involved in the 
formation and metabolism of bile acids a series of 
studies has been initiated dealing with the effects of 
carbon monoxide and phenobarbital administration 
on these reactions. A recent communication reported 
* The following systematic names are given to bile acids re- 
ferred to by trivial names: cholic acid, ICY, 701, 12&trihy- 
droxy-Sp-cholanoic acid; wmuricholic acid, ICY, 60, 701- 
trihydroxy-Spcholanoic acid; p-muricholic acid, 3& 60, 
7p-trihydroxy-Sp-cholanoic acid; chenodeoxycholic acid, 
3ce,7&dihydroxy-Sp-cholanoic acid; deoxycholic acid, 3c~., 
1201-dihydroxy-Sp-cholanoic acid; lithocholic acid, 3&hy- 
droxy-Spcholanoic acid. 
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the results with the 7o-hydroxylase catalyzing the con- 
version of cholesterol into cholest-5-ene-3/j, 7ol-diol 
and with the 12cu-hydroxylase catalyzing the conver- 
sion of 7a-hydroxycholest4en-3-one into 7q 12o- 
dihydroxycholest4en-3-one [S] _ Evidence was ob- 
tained to indicate that these hydroxylases differed 
from that (those) catalyzing the hydroxylation of 
drugs and steroid hormones. The present report de- 
scribes the results with the 7c+hydroxylase catalyzing 
the conversion of taurodeoxycholic into taurocholic 
acid and the 6&hydroxylase(s) catalyzing the 6/3-hy- 
droxylation of taurochenodeoxycholic acid and 
lithocholic (taurolithocholic) acid. 
2. Materials and methods 
Tritium-labeled taurodeoxycholic acid (8.3 pC/mg) 
and taurochenodeoxycholic acid (7.3 &/mg) were 
synthesized from tritium-labeled deoxycholic acid and 
chenodeoxycholic acid as described by Norman [6]. 
24-14C lithocholic acid (5 &/mg) was obtained from 
New England Nuclear Corp., Boston, Mass. and 4-14C 
androst4ene-3,17-dione (2.4 $/mg) from Radio- 
chemical Centre, Amersham, England. Pyridine nucleo- 
tides, D,L-isocitric acid and isocitric dehydrogenase 
(type IV) were obtained from Sigma Chemical Co., 
St. Louis, MO. This enzyme preparation contains 10 mg 
of protein per ml and 1 mg of protein converts 4 
pmoles of isocitrate into cw-ketoglutarate per min. 
White male rats of the Sprague-Dawley strain 
weighing 150-200 g were used. Phenobarbital (100 
mg/kg body weight), dissolved in 1 ml of saline, was 
administered intraperitoneally daily for 6 days. Control 
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rats were injected with saline. Liver homogenates, 20% 
(w/v), were prepared in a modified Bucher medium, 
pH 7.4, and the microsomal fraction was isolated as 
described previously [5] . The protein concentration 
of the microsomal fraction was determined with a 
micro-Kjeldahl method [7]. 
CONTROL TREAT ED 
The incubation mixtures consisted of 0.5-1.5 ml 
of microsomal fraction, diluted to 3 ml with Bucher 
medium, and an NADPH-generating system consist- 
ing of 0.03 pmoles of MnCl,, 3 pmoles of NADP, 
12.5 pmoles of isocitrate and 10 ~1 of isocitric dehy- 
drogenase solution. The substrates were added as 
follows: taurodeoxycholic acid, 200 pg in 50 ~1 of 
Bucher medium; taurochenodeoxycholic acid, 150 pg 
in 200 ~1 of Bucher medium; lithocholic acid, 80 pg 
in 0.5 ml of 25% aqueous ethanol (v/v); androst-4- 
ene-3,17-dione, 21Opg in 50 ~1 of acetone; amino- 
pyrine, 3.6 mg in 1 ml of Bucher medium. Incuba- 
tions were conducted at 37” for 20 min except those 
with androst4-ene-3,17-dione, which were run for 
5 min. 
CONTROL TREATED 
D 
100 - 
Incubations with taurodeoxycholic and taurochen- 
odeoxycholic acid were terminated by the addition 
of an equal volume of 95% aqueous ethanol (v/v). 
After filtration the solution was hydrolyzed with 1 M 
KOH for 12 hr at 1 IO”. The mixture was acidified 
with 6 M HCl and extracted with ether. The ether 
extract was washed with water until neutral and the 
solvent was evaporated. The residue of the ether ex- 
tract was chromatographed on a column of hydro- 
phobic Hyflo SuperCel with a phase system consist- 
ing of methanol-water (150 ml: 150 ml) as moving 
phase and chloroform-heptane (45 ml: 5 ml) as 
stationary phase [8]. Incubations with lithocholic 
acid were terminated by the addition of an equal 
volume of 95% aqueous ethanol (v/v). After filtra- 
tion the mixture was acidified with 0.2 M HCI and 
extracted with ether. The ether extract was washed 
with water until neutral and the solvent was eva- 
porated. The residue was chromatographed on a 
column of hydrophobic Hyflo SuperCel with phase 
system F 2 [8] . Incubations with androst-+ene-3,17- 
dione and aminopyrine were analyzed as described 
recently [5] . 
CONTROL TREATED 
Fig. 1. Effect of phenobarbital treatment on the hydroxyla- 
tion of taurodeoxycholic acid, taurochenodeoxycholic acid, 
lithocholic acid and androst-4-ene3,17-dione and on the oxi- 
dative demethylation of aminopyrine. Control, control rat; 
treated, phenobarbital-treated rat. A, 7&-hydroxylation of 
taurodeoxycholic acid; B, 6p-hydroxylation of taurocheno- 
deoxycholic acid; C, 6phydroxylation of lithocholic acid; 
D, conversion of androst-4-ene-3,17-dione into polar products 
E, formation of formaldehyde from aminopyrine. The 
values listed below each other were obtained with liver horn- 
genate from the same animal. 
3. Results 
Radioactivity was determined with a methane gas The hydroxylation of taurodeoxycholic acid, 
flow counter except in the case of incubations with taurochenodeoxycholic acid and lithocholic acid, 
androst-4-ene-3,17-dione where radioactivity was meas- catalyzed by the microsomal fraction of liver homo- 
ured with a Packard scintillation counter model 4322. genate fortified with an NADPH-generating system, 
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was studied in control rats and phenobarbital-treated 
rats. The hydroxylated products formed were the 
same in both groups of animals. Taurodeoxycholic 
acid was hydroxylated in the 7o-position to yield 
taurocholic acid. The identification was carried out 
after hydrolysis to cholic acid, which was crystallized 
to constant specific radioactivity after addition of 
authentic cholic acid. Taurochenodeoxycholic acid 
was converted into a mixture of tauro-o-muricholic 
acid (80-90%) and tauro-&muricholic acid (lo-20%). 
These metabolites were identified after hydrolysis 
by their chromatographic properties only. Extracts 
of incubations with taurochenodeoxycholic acid 
were hydrolyzed and the hydrolyzed mixture was 
chromatographed to separate chenodeoxycholic acid 
from cy- and /_I-muricholic acids. The fractions con- 
taining the muricholic acids were chromatographed 
together with unlabeled cholic acid with phase system 
C 1 [S] . The radioactivity was eluted in two peaks, 
one appearing slightly before and one after the titra- 
tion peak of cholic acid. These elution patterns are 
typical of (Y- and /3-muricholic acid, respectively. 
Lithocholic acid was converted into 3o, 6&dihydroxy- 
S/3-cholanoic acid, identified by its chromatographic 
behaviour in thin layer chromatography with phase 
system S 11 [9] . When taurolithocholic acid was 
incubated,, the same product (as taurine conjugate) 
was formed to the same extent, Practically no hydroxy- 
lation of the bile acids was obtained when NADH was 
used instead of NADPH. 
Fig. 1 summarizes the effect of phenobarbital on 
hydroxylation of the three bile acids. For comparison 
the oxidative demethylation of aminopyrine and the 
hydroxylation of androst+ene-3,17-dione were 
measured. On average, the 7ol-hydroxylation of tauro 
deoxycholic acid was 2.7 times more efficient in 
phenobarbital-treated rats than in control rats. The 
6/I-hydroxylation of taurochenodeoxycholic acid was 
2.8 times and the 6&hydroxylation of lithocholic 
acid 3.8 times more efficient in phenobarbital-treated 
rats. The increase in oxidative demethylation of 
aminopyrine and in hydroxylation of androst4ene- 
3,17-dione was 3.2 and 5.7 times, respectively. 
The rate of hydroxylation of taurodeoxycholic 
acid, taurochenodeoxycholic acid and lithocholic 
acid as well as the rate of oxidative demethylation of 
aminopyrine were found to be the same in an atmos- 
phere of 4% oxygen and 96% nitrogen as in air. In an 
atmosphere of 4% oxygen, 56% nitrogen and 40% car- 
bon monoxide the 6/3_hydroxylation of taurocheno- 
deoxycholic acid and of lithocholic acid was inhibited 
by, on average, 83 and 62%, respectively, whereas the 
7o-hydroxylation of taurodeoxycholic acid was inhi- 
bited only by 14%. The oxidative demethylation of 
aminopyrine was inhibited almost completely, 95%. 
The inhibition of the 6/I-hydroxylation by carbon 
monoxide was reversed about 50% by light. 
4. Discussion 
The results of the present work and that reported 
recently [5] show differences between the hydroxy- 
lation reactions in the biosynthesis and metabolism of 
bile acids. With respect to the effect of phenobarbital 
the two hydroxylations involved in the de nova syn- 
thesis of bile acids, the 7o-hydroxylation of choles- 
terol and the 12o-hydroxylation of 7c+hydroxy- 
cholest4en-3-one, were unaffected or inhibited, 
whereas a two- to four-fold stimulation was observed 
for the other three hydroxylations, the 7cr-hydroxy- 
lation of taurodeoxycholic acid and the 6&hydroxy- 
lation of taurochenodeoxycholic acid and lithocholic 
acid. These reactions are involved in the interconver- 
sion of bile acids. In parallel experiments the oxidative 
demethylation of aminopyrine and the hydroxylation 
of androstlt-ene3,17-dione were found to be stimu- 
lated three- to six-fold by phenobarbital administra- 
tion in agreement with previous work by others 
[lO,ll]. 
Carbon monoxide was found to affect differently 
the three hydroxylations stimulated by phenobarbital 
administration. The 7cu-hydroxylation of taurodeo 
xycholic acid was practically unaffected, whereas the 
6phydroxylation reactions were inhibited markedly. 
Recently, Voigt et al. [ 12,131 have also found that 
the 6/3-hydroxylation of taurochenodeoxycholic acid 
is inhibited by carbon monoxide. The 12o-hydroxy- 
lation of 7c+hydroxycholest4en-3-one has been re- 
ported to be partly inhibited [ 141 or not at all inhi- 
bited [ 151. With respect to the effect of carbon mono- 
xide on the 7or-hydroxylation of cholesterol no con- 
clusive information is available at present. 
The drug-metabolizing enzyme system is character- 
ized by being stimulated by phenobarbital admini- 
stration and inhibited by carbon monoxide. Of the 
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five hydroxylations in the formation and metabolism 
of bile acids studied in the present and previous re- 
port [5], two, the 6&hydroxylations, showed the 
same properties as the drug-metabolizing enzyme sys- 
tem with respect to effects of phenobarbital and car- 
bon monoxide. In fact, Voigt et al. [ 12,131 have 
recently provided evidence that NADPH-cytochrome 
c reductase as well as cytochrome Pd50 are involved 
in the 6/3-hydroxylation of taurochenodeoxycholic 
acid. The other three hydroxylations, the 7cw-hydroxy- 
lation of cholesterol, the 12cll-hydroxylation of 7cu- 
hydroxycholest4en-3-one and the 7o+hydroxylation 
of taurodeoxycholic acid, were found to differ from 
each other and from the drug-metabolizing enzyme 
system in response to phenobarbital administration 
and carbon monoxide. These differences appear to 
be explained most easily by assuming the participa- 
tion of different hydroxylating systems. Such an inter- 
pretation of the results would not support the con- 
cept of a single hydroxylase system in liver micro- 
somes catalyzing the hydroxylation of steroids and 
drugs. 
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